Biotech has roared back to life the past couple years, perhaps more than any other U.S. economic sector. Seattle’s biotech community is no different. Last year’s signs of revival include the ascendance of Juno Therapeutics, the burgeoning pipeline of Seattle Genetics, the kickoff of a study that could become a key part of the national precision medicine initiative, and Celgene’s decision to build an R&D center in town.
There were lows, too, such as Amgen’s decision to leave town, but the momentum is in Seattle’s favor. On May 6, we’re gathering for a half-day of conversation and debate about Seattle biotech in 2015 and beyond. We’ll discuss topics such as the region’s expertise in cancer immunotherapy; the relationship between for-profit biotechs and the city’s vibrant nonprofit research core; the identity of the next great “anchor” company; and the fate of Amgen’s Helix campus, built only 10 years ago for decades of biotech use.
How should Seattle biotech seize the momentum? Join us at the Fred Hutchinson Cancer Research Center to take part in the discussion.